VIVUS, Opposition. (NASDAQ: VVUS) at the moment declared definite results from a stage 3, placebo-controlled clinical try-out of the investigational cure-all avanafil representing the discussion of ed (ED) in patients shadowing a cardinal prostatectomy. The read (REVIVE-RP, TA-303) met the totality of fundamental endpoints by means of demonstrating recovery from line in expansive use as careful near the Genital Happen upon Life (both SEP2 and SEP3) and improvements in the Ecumenical Thesaurus of Expansive Mission (IIEF). The particularized results of the swot purposefulness be presented on June 17, 2011 at the Crab Survivorship and Propagative Trim Symposium in Educator, DC.
“Patients who own undergone a cardinal prostatectomy over receive critical ed. Consideration advancements in process, it potty grab various months or life to stabilize erections. Fundamental prostatectomy patients are arduous to consider but the definite results of avanafil in these patients urge that, if authorized, avanafil could be an fetching action opportunity,” commented Toilet Mulhall, M.D., Official, Macho Sex & Procreative Medicament Papers, Commemorative Sloan Technologist Person Building and an tec in the learn about. ”The experiment met the totality of the pre-eminent endpoints and inclusive results of the swot purposefulness be presented mid the prospect Human Survivorship Symposium to be held in Educator DC.”